Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Pär Stattin"'
Autor:
Montse Soriano Gabarró, Jihong Zong, Juha Mehtälä, Houssem Khanfir, Gunnar Brobert, Zdravko P. Vassilev, Pär Stattin
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0227552 (2020)
PLoS ONE
PLoS ONE
Background Among prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. PC treatments may be associated with side effects, including second primary malignancies (SPM). There is limited information on the incidence of SPM amo
Autor:
Elin Thysell, Maria Nilsson, Sofia Halin Bergström, Anders Bergh, Anders Widmark, Emma Jernberg, Pernilla Wikström, Pär Stattin, Hanibal Hani Adamo
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157280 (2016)
PLoS ONE
PLoS ONE
Aggressive tumors induce tumor-supporting changes in the benign parts of the prostate. One factor that has increased expression outside prostate tumors is hemoxygenase-1 (HO-1). To investigate HO-1 expression in more detail, we analyzed samples of tu
Autor:
Pär Stattin, Pernilla Andersson, Pernilla Wikström, Anders Bergh, Lars Egevad, Peter Hammarsten, Torvald Granfors, Tove Dahl Scherdin, Christina Hägglöf
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0164016 (2016)
PLoS ONE
PLoS ONE
In the present study we have investigated whether Caveolin-1 expression in non-malignant and malignant prostate tissue is a potential prognostic marker for outcome in prostate cancer patients managed by watchful waiting. Caveolin-1 was measured in pr
Autor:
Göran Hallmans, Hans Concin, Randi Selmer, Hanno Ulmer, Pär Stattin, Jonas Manjer, Christel Häggström, Börje Ljungberg, Håkan Jonsson, Kilian Rapp, Steinar Tretli, Gabriele Nagel, Tone Bjørge, Anders Engeland, Tanja Stocks, Martin Almqvist
Publikováno v:
PLoS ONE; 8(2), no e57475 (2013)
PLoS ONE
PLoS ONE, Vol 8, Iss 2, p e57475 (2013)
PLoS ONE
PLoS ONE, Vol 8, Iss 2, p e57475 (2013)
Previous studies have shown that obesity and hypertension are associated with increased risk of renal cell carcinoma (RCC), but less is known about the association to other metabolic factors. In the Metabolic Syndrome and Cancer project (Me-Can) data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac1e0a994e41a8aad3020e2a5c993113
https://lup.lub.lu.se/record/3657405
https://lup.lub.lu.se/record/3657405
Autor:
Lars Egevad, Andreas Josefsson, Peter Hammarsten, Pär Stattin, Torvald Granfors, Christopher J. Fowler, Mariateresa Cipriano
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e47994 (2012)
PLoS ONE
PLoS ONE
BACKGROUND: In the present study, we have investigated the prognostic usefulness of phosphorylated Akt immunoreactivity (pAkt-IR) in prostate cancer using a well-characterised tissue microarray from men who had undergone transurethral resection due t